NASDAQ:DCPH Deciphera Pharmaceuticals (DCPH) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free DCPH Stock Alerts $14.18 -0.44 (-3.01%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$14.00▼$14.7350-Day Range$14.18▼$17.3652-Week Range$9.90▼$17.73Volume527,033 shsAverage Volume523,099 shsMarket Capitalization$1.15 billionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Deciphera Pharmaceuticals alerts: Email Address Deciphera Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside62.2% Upside$23.00 Price TargetShort InterestBearish11.45% of Float Sold ShortDividend StrengthN/ASustainability-1.60Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.16) to ($1.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.78 out of 5 starsMedical Sector281st out of 907 stocksPharmaceutical Preparations Industry119th out of 422 stocks 3.4 Analyst's Opinion Consensus RatingDeciphera Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDeciphera Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.45% of the float of Deciphera Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDeciphera Pharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.Change versus previous monthShort interest in Deciphera Pharmaceuticals has recently decreased by 5.12%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDeciphera Pharmaceuticals does not currently pay a dividend.Dividend GrowthDeciphera Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDeciphera Pharmaceuticals has received a 50.76% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Ripretinib", "Preclinical research services for physical health", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Deciphera Pharmaceuticals is -1.60. Previous Next 2.2 News and Social Media Coverage News SentimentDeciphera Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Deciphera Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for DCPH on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Deciphera Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.43% of the stock of Deciphera Pharmaceuticals is held by insiders.Percentage Held by Institutions70.96% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.16) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Deciphera Pharmaceuticals is -6.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Deciphera Pharmaceuticals is -6.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDeciphera Pharmaceuticals has a P/B Ratio of 3.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Deciphera Pharmaceuticals Stock (NASDAQ:DCPH)Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Read More DCPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DCPH Stock News HeadlinesApril 9, 2024 | businesswire.comDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumMarch 25, 2024 | msn.comNovo Nordisk strikes deal worth up to $1.1 billion to expand cardio businessApril 25, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 24, 2024 | finance.yahoo.comCompanies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In GrowthFebruary 27, 2024 | businesswire.comDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesFebruary 12, 2024 | finance.yahoo.comWall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to TradeFebruary 8, 2024 | finance.yahoo.comAnalysts Are Updating Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Estimates After Its Annual ResultsFebruary 7, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Deciphera Pharmaceuticals on Strong Q4 Performance and Promising Drug ProspectsApril 25, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. February 7, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Deciphera Pharmaceuticals (DCPH), ACADIA Pharmaceuticals (ACAD)February 7, 2024 | finance.yahoo.comDeciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues BeatFebruary 6, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals: Sustained Growth and Market Expansion Drive Buy RatingFebruary 6, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals: Strong Buy Rating on Robust Financials and Promising PipelineFebruary 6, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals, Inc. Q4 Loss beats estimatesFebruary 5, 2024 | msn.comDeciphera Pharmaceuticals Q4 2023 Earnings PreviewFebruary 2, 2024 | nz.finance.yahoo.comSeattle woman who returned Costco couch after 2.5 years goes viral, sparks ethics debateFebruary 1, 2024 | finance.yahoo.comDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024February 1, 2024 | finance.yahoo.comNurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseFebruary 1, 2024 | finance.yahoo.comDeciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 31, 2024 | uk.investing.comDeciphera Pharmaceuticals LLC (DCPH)January 29, 2024 | finance.yahoo.comStrong week for Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders doesn't alleviate pain of three-year lossJanuary 18, 2024 | finance.yahoo.comDeciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumJanuary 12, 2024 | businesswire.comGENESIS Pharma Announces an Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize RIPRETINIB in 14 EU Markets in Central and Eastern EuropeJanuary 11, 2024 | markets.businessinsider.comDeciphera Pharmaceuticals: A Strong Buy on Impressive Qinlock Sales and Promising Vimseltinib ProspectsJanuary 9, 2024 | seekingalpha.comDeciphera: Upside Potential For The Patient InvestorJanuary 8, 2024 | seekingalpha.comDeciphera Pharmaceuticals: Moving The Needle Where It CountsJanuary 5, 2024 | businesswire.comDeciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical ...See More Headlines Receive DCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/06/2024Today4/25/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:DCPH CUSIPN/A CIK1654151 Webwww.deciphera.com Phone(781) 209-6400FaxN/AEmployees355Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$30.00 Low Stock Price Target$16.00 Potential Upside/Downside+62.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-194,940,000.00 Net Margins-119.33% Pretax Margin-119.07% Return on Equity-49.44% Return on Assets-38.41% Debt Debt-to-Equity RatioN/A Current Ratio3.80 Quick Ratio3.59 Sales & Book Value Annual Sales$163.36 million Price / Sales7.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.38 per share Price / Book3.24Miscellaneous Outstanding Shares80,800,000Free Float77,221,000Market Cap$1.15 billion OptionableOptionable Beta0.39 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Steven L. Hoerter (Age 53)President, CEO & Director Comp: $1.24MMr. Thomas Patrick Kelly J.D. (Age 53)Executive VP, CFO & Treasurer Comp: $778.85kMr. Daniel C. Martin (Age 49)Senior VP & Chief Commercial Officer Comp: $711.42kDr. Matthew L. Sherman M.D. (Age 68)Executive VP & Chief Medical Officer Comp: $865.62kDr. Kevin Brodbeck Ph.D.Senior VP & Chief Technical OfficerDr. Dashyant Dhanak Ph.D. (Age 63)Executive VP & Chief Scientific Officer Jennifer LarsonSenior Vice President of Finance & Investor RelationsMr. Jeffrey M. Held J.D.Senior VP & General CounselMs. Lisa Amaya PriceSenior VP & Chief Human Resources OfficerMs. Jama Pitman (Age 44)Senior VP & Chief Development Officer More ExecutivesKey CompetitorsPieris PharmaceuticalsNASDAQ:PIRSCollegium PharmaceuticalNASDAQ:COLLGemini TherapeuticsNASDAQ:GMTXAbCellera BiologicsNASDAQ:ABCLMirum PharmaceuticalsNASDAQ:MIRMView All CompetitorsInsiders & InstitutionsDiversified Trust CoBought 778 shares on 4/18/2024Ownership: 0.016%Los Angeles Capital Management LLCBought 18,494 shares on 4/5/2024Ownership: 0.023%Fisher Asset Management LLCBought 62,372 shares on 3/5/2024Ownership: 0.077%Goldman Sachs Group Inc.Bought 290,968 shares on 3/1/2024Ownership: 2.856%Parkman Healthcare Partners LLCSold 36,378 shares on 2/15/2024Ownership: 0.694%View All Insider TransactionsView All Institutional Transactions DCPH Stock Analysis - Frequently Asked Questions Should I buy or sell Deciphera Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DCPH shares. View DCPH analyst ratings or view top-rated stocks. What is Deciphera Pharmaceuticals' stock price target for 2024? 5 equities research analysts have issued twelve-month price targets for Deciphera Pharmaceuticals' stock. Their DCPH share price targets range from $16.00 to $30.00. On average, they anticipate the company's share price to reach $23.00 in the next year. This suggests a possible upside of 62.2% from the stock's current price. View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts. How have DCPH shares performed in 2024? Deciphera Pharmaceuticals' stock was trading at $16.13 on January 1st, 2024. Since then, DCPH stock has decreased by 12.1% and is now trading at $14.18. View the best growth stocks for 2024 here. Are investors shorting Deciphera Pharmaceuticals? Deciphera Pharmaceuticals saw a decrease in short interest in April. As of April 15th, there was short interest totaling 5,750,000 shares, a decrease of 5.1% from the March 31st total of 6,060,000 shares. Based on an average daily trading volume, of 525,500 shares, the days-to-cover ratio is presently 10.9 days. Approximately 11.5% of the company's shares are sold short. View Deciphera Pharmaceuticals' Short Interest. When is Deciphera Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our DCPH earnings forecast. How were Deciphera Pharmaceuticals' earnings last quarter? Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its quarterly earnings results on Tuesday, February, 6th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.04. The firm earned $48.30 million during the quarter, compared to analyst estimates of $45.93 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 49.44% and a negative net margin of 119.33%. The business's revenue was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.60) EPS. What ETFs hold Deciphera Pharmaceuticals' stock? ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Tema Oncology ETF (CANC), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA) and iShares Genomics Immunology and Healthcare ETF (IDNA).ALPS Medical Breakthroughs ETF (SBIO). What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO? 3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Deciphera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL). When did Deciphera Pharmaceuticals IPO? Deciphera Pharmaceuticals (DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers. Who are Deciphera Pharmaceuticals' major shareholders? Deciphera Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, Matthew L Sherman, Steven L Hoerter and Thomas Patrick Kelly. View institutional ownership trends. How do I buy shares of Deciphera Pharmaceuticals? Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DCPH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
